Almirall Posts Strong H1 2026 Growth on Biologics Momentum
Event summary
- Net sales grew 7.5% YoY to €602.7M, EBITDA up 23.7% YoY to €150.7M
- European Dermatology business surged 18.1% YoY to €341.9M
- Ebglyss® sales jumped 88.2% YoY to €84.5M, Ilumetri® up 10.5% YoY to €125.2M
- R&D pipeline expanded with four ongoing PoC/Phase II studies and two planned by year-end
The big picture
Almirall's strong H1 2026 results reflect the growing demand for advanced dermatology treatments, particularly biologics. The company's focus on innovation and strategic partnerships positions it well in a competitive pharmaceutical landscape, though sustaining growth will depend on successful R&D execution and market differentiation.
What we're watching
- Biologics Momentum
- Whether Almirall can sustain the rapid growth of Ebglyss® and Ilumetri® in competitive dermatology markets.
- R&D Execution
- The pace at which Almirall advances its pipeline, particularly with first readouts expected by year-end.
- Strategic Partnerships
- How collaborations like Certest Biotec and Huaota will impact innovation in rare dermatologic diseases.
Related topics